...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Cephalalgia >Safety and efficacy of PNU-142633, a selective 5-HT1D agonist, in patients with acute migraine.
【24h】

Safety and efficacy of PNU-142633, a selective 5-HT1D agonist, in patients with acute migraine.

机译：选择性5-HT1D激动剂PNU-142633在急性偏头痛患者中的安全性和有效性。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

In this randomized, double-blind, placebo-controlled, parallel-group study, patients received a single 50-mg oral dose of a 5-HT(1D) agonist, PNU-142633 (n = 34), or matching placebo (n = 35) during an acute migraine attack. No statistically significant treatment effects were observed at 1 and 2 h after dosing, even after stratifying by baseline headache intensity. At 1 and 2 h post-dose, 8.8% and 29.4% of the PNU-142633 group, respectively, and 8.6% and 40.0% of the placebo group, respectively, experienced headache relief; 2.9% and 8.8% of the PNU-142633 group and 0% and 5.7% of the placebo group were free of headache pain. Adverse events associated with PNU-142633 treatment included chest pain (two patients) and QTc prolongation (three patients). Results from this study suggest that anti-migraine efficacy is not mediated solely through the 5-HT(1D) receptor subtype, although this receptor may contribute, at least in part, to the adverse cardiovascular effects observed with 5-HT agonist medications.
机译：在这项随机，双盲，安慰剂对照，平行组研究中，患者接受了50 mg口服单剂量的5-HT（1D）激动剂PNU-142633（n = 34）或匹配的安慰剂（n = 35）在急性偏头痛发作期间。即使在基线头痛强度分层后，给药后1和2小时也未观察到统计学上显着的治疗效果。给药后1小时和2小时，PNU-142633组分别为8.8％和29.4％，安慰剂组分别为8.6％和40.0％。 PNU-142633组的2.9％和8.8％以及安慰剂组的0％和5.7％没有头痛。与PNU-142633治疗相关的不良事件包括胸痛（两名患者）和QTc延长（三名患者）。这项研究的结果表明，抗偏头痛功效并非仅通过5-HT（1D）受体亚型介导，尽管该受体可能至少部分地导致了使用5-HT激动剂药物观察到的不良心血管作用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号